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The function of the nervous system depends on the highly specific
pattern of connections formed between neurons during development.
The specificity of these connections requires neurite extension toward
the correct targets guided by the growth cone, and refinement and
remodeling of the initial pattern of connections, referred to as synaptic
plasticity, that are dependent on patterns of synaptic activity (1). The
growth cone receives several kinds of environmental signals, such as
diffusible chemoattractants and chemorepellants, extracellular matrix
components, and cell adhesion molecules (2), and then the growth cone
interprets these signals to generate a change in its shape and motility,
that results in the advance, turning, or collapse of the growth cone.
The Rho family of small GTPases, including Rae, Cdc42, and Rho,
has been implicated in the reorganization of the actin cytoskeleton and
subsequent morphological changes in various cell types (3, 4). Like
other GTPases of the Ras superfamily, they serve as molecular swithes
by cycling between an inactive GDP-bound state and an active GTP-
bound state. Activation of the Rho family proteins requires GDP-GTP
exchange catalysed by various guanine-nucleotide exchange factors
(GEFs), and their activation is also regulated by GTPase-activating
proteins (GAPs) which stimulate their intrinsic GTPase activities. In
addition, guanine-nucleotide dissociation inhibitors (GDIs) inhibit the
exchange of GDP for GTP and might also serve to regulate their
association with membranes (Fig. 0-1). Recent studies have shown that
the Rho family proteins play critical roles in the regulation of the
cytoskeleton required for neurite extension and retraction. Studies on
neuronal cell lines have shown that Rae and Cdc42 are involved in the
formation of lamellipodia and filopodia of the growth cone,
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respectively, and they are required for the outgrowth of neurites. On
the other hand, Rho is required for the collapse of the growth cone and
the retraction of neurites (5-7, Fig. 0-2). The functions of these
GTPases have been also examined in vivo, and defects in the regulation
of these GTPase activities have been demonstrated to affect the
development of the nervous system (8-10).
PC12 cells are derived from rat pheochromocytomas and serve as a
useful model system for the study of neuronal differentiation. When
PC12 cells are exposed to nerve growth factor (NGF) for several days,
they acquire many features of sympathetic neurons, such as outgrowth
of neurites (11). Previous studies have found that the activation of a
certain heterotrimeric GTP-binding protein (G-protein)-coupled
receptor, such as lysophosphatidic acid (LPA) receptor, caused the rapid
collapse of growth cones and retraction of extended neurites in NGF-
differentiated PC12 cells (12-14). Clostridium botulinum C3
exoenzyme, which specifically ADP-ribosylates Rho and suppresses the
actions of Rho (15, 16), inhibits the receptor-mediated growth cone
collapse and neurite retraction (17, 18), indicating that Rho is required
for these morphological changes. However, the intracellular
mechanisms involved in Rho-mediated morphological changes in
neuronal cells have not yet been elucidated.
In this study, the auther has investigated the signal transduction
pathways upstream and downstream of Rho to induce growth cone
collapse and neurite retraction in NGF-differentiated PC12 cells. The
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Roles of Rho family small G proteins in navigation of the grewth cone.
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Abbreviations used in the text
GEF, guanine nucleotide exchange factor
GAP, GTPase-activating protem
GDI, guanine nucleotide dissociation inhibitor
NGF, nerve growth .factor




MLC, myosin light chain
PT, permssis toxin
PCR, polymerase chain reaction




PKA, protein kinase A
Bt2cAMP, dibutyry1 cAMP
DMEM, Dulbecco's modified Eagle's medium
-4-
1. p160 RhoA-binding Kinase ROKor Induces Neurite
    Retraction
Summary
    It is well known that activation of Rho by extracellular simuli, such
as LPA, causes neurite retraction through small GTPase Rho in NGF-
differentiated PC12 cells. However, a potential downstream effector of
Rho to induce neurite retraction was not identified. Here I examined the
effect of p160 RhoA-binding kinase ROKct, a target for RhoA recently
identified, on the morphology of NGF-differentiated PC12 cells.
Microiajection of the catalytic domain of ROKct rapidly induced neurite
retraction similar to that induced by microiajection of a constitutively
active RhoA, RhoAVi4, while microinjection of the kinase-deficient
catalytic domain of ROKa did not induce neurite retraction. This
morphological change was occurred even' though C3 exoenzyme, which
was known to inactivate Rho, had been preiajected. On the other hand,
microiojection of the Rho-binding domain or the pleckstrin-homology
domain of ROKct inhibited the prostaglandin EP3 receptor-induced
neurite retraction. These results demonstrate that ROKct induces
neurtte retraction acting downstream of Rho in neuronal cells.
-5 --
Introduction
When cells are activated by extracellular stimuli, inactive GDP-
bound fonn of Rho is converted to active GTP-bound form of Rho, and
once activated, Rho probably interacts with its specific targets, leading
to a variety of biological functions (Fig. 0-1). Recently, several target
proteins that interact only with GTP-bound form of Rho have been
identified, including p128 protein kinase N (19, 20), p160 RhoA-
binding kinase ROKa (21) also known as its bovine counterpart Rho-
kinase (22) or its mouse counterpart ROCK-II (23), rhophilin (19),
rhotekin (24), and p140mDia (25). Among them, ROKa has been
reported to be involved in several functions of Rho: the regulation of
myosin phosphorylation (26, 27), the formation of stress fibers and
focal adhesions (28, 29), and the regulation of cytokinesis (30).
In NGF-differentiated pe12 cells, activation of Rho by several
extracellular stimuli causes collapse of growth cones and retraction of
extended neurites (18, 31). These effects appear to be induced by the
contractility of the actin-based cytoskeleton (17, 32). However, a
downstream effector of Rho to induce neurite retraction has not yet
been identified. In the present study, I have examined the putative role
of ROKa in the receptor-mediated neurite retraction in the NGF-
differentiated PC12 cells. I demonstrate that ROKa is involved in the
receptor-mediated neurite retraction acting downstream of Rho and that
the activation of ROKa is sufficient for inducing neurite retraction.
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Results
Neurite Retraction Ind"ced by RhoAV14
    I obtained the evidence that M&B28767, an EP3 receptor agonist,
induced neurite retraction in the EP3 receptor-expressing PC12 cells,
and that this morphological change was completely inhibited when the
cells were microinjected with C3 exoenzyme, which ADP-ribosylates
and inactivates Rho (15, 16), indicating that the activation of Rho was
required for the EP3 receptor-induced neurite retraction (31, also see
Chapter 3). To determine whether activation of Rho is sufficient for
inducing neurite retraction in the PC12 cells, I microinjected a
censtitutively activated recombinant RhoA, RhoAVi4, into the NGF-
differentiated PC12 cells and examined its effect. Microinjection of
RhoAVi4 into the cytoplasm caused retraction of the neurites within 30
min (Fig. 1-1, C and D). More than 70% of the iajected cells retracted
their neurites (Fig, 1-5), This morphological change was similar to that
stimulated by M&B28767 (Fig. 1-1,A andB), The neurite-retracted
cells by microinjection of RhoAVi4 was not stainined with trypan blue
(data not shown), indicating that they did not undergo cell death. On the
other hand, RhoAVi4 containing a T37A substitution in the effector
region, RhoAVi4A37, had nQ efirect on the differentiated cells after
microinjection (Fig. 1-1, E and F, and Fig. 1-5), suggesting that this
mutation blocked the interaction of RhoA with its target to induce
,neurite retraction. This result also indicated that there were not any
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Figure 1-1. Neurite retraction induced by M&B28767 or microiajection
of RhoAV14. A and B, M&B28767-induced neurite retraction. The cells were
differentiated with NGF for 3 days and photographed before (A) and 30 min after (B)
addition of 1 pM M&B28767. C and D, microiojection of RhoAV14. The cells were
differentiated with NGF for 3 days and photographed before (C) and 30 min after (D)
microirijection of 1 mg/mi of RhoAV14. E and F, microiojection of RhoAV14A37. The
cells were differentiated with NGF for 3 days and photographed befbre (C) and 30 min
after (D) microirijection of 1 mg/mi of RhoAV14A37. The arrows indicate iojected cells.
The results shown are representative of three independent experiments. The bar
represents 50 pm.
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Neurite Retractien induced by ROKa
    Previous studies have suggested that the generation of actin-based
contractile forces was required for neurite retraction (17, 32). Among
several targets of Rho, ROKor appears to panicipate in Rho-dependent
contractile events, such as the formation of stress fibers (28, 29) and the
regulation of cytokinesis (30). By Northern blot analysis, ROKct was
expressed in the NGF-differentiated PC12 cells (data not shown).
Therefore, I examined whether ROKor was involved in the Rho-
mediated neurite retraction in the NGF-differentiated PC12 cells.
ROKct contains the catalytic domain in its amino-terminus, the coiled-
coil domain, the Rho-binding domain, and the pleckstrin homology (PH)
domain in its carboxy-terminus (Fig. 1-2). It was recently shown that
the truncation mutant of ROKct containing the catalytic domain
displayed constitutive kinase activity without addition of an active form
        1 CatalyticDemain Coiled-coilDomain PHDomain 1379
  ROKct
                                Rho-binding Domain (sED2re :: !! 43                           CD-ROKct
                           CD-ROKct Kl12G
         KI12 -G                                932 1065                RBD-ROKct on
                                        1116 1379                pHD-RoKct (El:D--=:
Fig. 1-2. Structure of ROKct.
nv "ttft-'twrtntrTr-
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of Rho, while the Rho-binding domain and the PH domain of ROKct
served as dominant negative forms of the kinase (28, 29). Based on
these characters, we generated recombinant proteins containing these
domains as fusion proteins with gulutathione S-transferase (GST): the
catalytic domain of ROKct (CD-ROKct, amino acids 1-543), the kinase-
deficient mutant of CD-ROKct (CD-ROKctKii2G), the Rho-binding
domain of ROKct (RBD-ROKct, amino acids 932-1065), and the PH
domain of ROKct (PHD-ROKct, amino acids 1116-1379) (Fig. 1-2). To
confirm that CD-ROKct really displayed constitutive kinase activity, I
examined its kinase activity using myosin light chain (MLC) as a
substrate. As shown in Fig. 1-3, CD-ROKct phosphorylated MLC,
while CD-ROKctKii2G or RBD-ROKct did not, indicating that CD-
ROKct is constitutively active. Then I microiajected these recombinant
proteins into the NGF-differentiated cells and analyzed their
morphologies.







Figure 1-3. Phosphorylation of MLC by ROKct. Isolated MLC (4 pg) was
incubated with 10 ng GST-RBD (lane 1), GST-CD-ROKct (lane 2), or GST-CD-
ROKctKl12G (lane 3) for 10 min at 30eC. Phosphorylated MLC was resolved by SDS-
PAGE and visualized by an image analyzer. The results shown are representative of
three independent experiments.
                        -- 10-
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After the cells had been microinjected with CD-ROKa, they rapidly
retracted their neurites within 30 min (Fig. 1-4, A and B, and Fig. 5).
This morphological change was similar to that induced by
microinj ection of RhoAv 14. The neurite-retracted cells by
microinjection of CD-ROKa was not stainined with trypan blue (data
not shown), indicating that they did not undergo cell death. On the
other hand, microinjection of CD-ROKaK1l2G had no effect (Fig. 1-4, C
and D, and Fig. 1-5), indicating that the kinase activity of CD-ROKa
was required for inducing neurite retraction. When the cells were
microinjected with C3 exoenzyme, the M&B28767-induced neurite
retraction was completely suppressed (Fig. 1-4, E and F). However, the
CD-ROKa-induced neurite retraction was not inhibited after the cells
had been microinjected with C3 exoenzyme (Fig. 1-4, G and H),
indicating that CD-ROKa acted downstream of Rho.
Figure 1-4. Neurite retraction induced by ROKa. A and B, microinjection of
CD-ROKa. The cells were differentiated with NGF for 3 days and photographed
before (A) and 30 min after (B) microinjection of 2 mg/rnl of CD-ROKa. C and D,
microinjection of CD-ROKaK112G. The cells were differentiated with NGF for 3 days
and photographed before (C) and 30 min after (D) microinjection of 2 mg/rnl of CD-
ROKaK112G. E and F, the effect of C3 exoenzyme on the M&B28767-induced neurite
retraction. After the NGF-differentiated cells microinjected with 100 !-lg/rnl of C3
exoenzyme had been preincubated for 30 min, they were photographed before (E) and
30 min after (F) addition of l!-lM M&B28767. G and H, the effect of C3 exoenzyme
on the CD-ROKa-induced neurite retraction. After the NGF-differentiated cells
microinjected with 100 !-lg/ml of C3 exoenzyme had been preincubated for 30 min, they
were photographed before (G) and 30 min after (H) rnicroinjection of 2 mg/ml of CD-
ROKa. The arrows indicate injected cells. The resl;1lts shown are representative of
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Figure 1-5. Quantification of effects of M&B28767, RhoA, and ROKct
on neurite retraction. After the cells had been differentiated with NGF for 3 days,
they were exposed to 1 uM M&B28767 or microiajected with the recombinant proteins
of the indicated mutants of RhoA or ROKct The percentages of nearite-retracted cells
were detemined 30 min after the addition of the agonist or the microiajection of the
proteins, as described under "Experimental Procedures". RhoAVI4 or RhoAV14A37
was injected at 1 mg/mi, and CD-ROKa or CD-ROKctKl 12G was injected at 2 mglml,
respectively, Data are the mean ± S.E. of triplicate experiments.
EllYlacts of the Rho-binding Domain and the PH Domain ofROKa on the
EP3 Receptor-mediated Neurite Retraction
    Next I microiajected RBD-ROKct or PHD-ROKct, which served as
dominant negative forms of ROKct, into the differentiated cells and
examined each effect on the M&B28767-induced neurite retraction.
When the cells had been microinjected with RBD-ROKor or PHD-
ROKct, the M&B28767-induced neurite retraction was inhibited (Fig. 1-
6). All the cells microiajected with RBD-ROKct or PHD-ROKct had no
response to M&B28767. These results suggest that ROKa is involved in
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the EP3 receptor-mediated neurite retraction in the PC12 cells. Taken
together, my results suggest that ROKct induces neurite retraction acting
downstream of Rho in the NGF-differentiated PC12 cells.
ff " :/
Figure 1-6. Effect of the Rho-binding domain and the PH domain of
ROKct on M&B28767-induced neurite retraction. The NGF-differentiated
cells were microiajected with 2 mglmi of RBD-ROKct (A and B), or 1 mgtml of PHD-
ROKct (C and D), and photographed before (A and C) and 30 min after (B and D)
addition of 1 pM M&B28767. The arrows indicate iajected cells. The results shown
are representative of three independent experiments. At least 20 cells were
microiojected in each experiment, and all cells microiojected gave the described
response. The bar represents 50 pm.
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Discussion
    In the present study,I have found that ROKct is involved in the
receptor-mediated neurite retraction acting downstream of Rho in NGF-
differentiated PC12 cells. Recently, ROKct was shown to be involved in
Rho-induced formation of stress fibers and focal adhesion in other cell
types such as fibroblasts. However, the organization of stress fibers
induced by constitutively active ROKa was apparently different from
that induced by lysophosphatidic acid or constitutively active Rho (28,
29), suggesting that additional signals were required for Rho-induced
stress fiber formation. In this study, however, microiajection of CD-
ROKa sufficiently induced neurite retraction similar to that induced by
RhoAVi4 even though C3 exoenzyme had been preiajected, while CD-
ROKctKii2G failed to induce neurite retraction (Figs. 1-4 and 1-5),
suggesting that the increase in the kinase activity of ROKct by Rho
appears to be sufficient for inducing neurite retraction. Since myosin-
binding subunit of myosin phosphatase and MLC are known to be
substrates for ROKct and activation of ROKor leads to phosphorylation
and activation of myosin (26, 27), neurite retraction may be induced by
ROKor-mediated regulation of myosin phosphorylation. In addition, it
was recently reported that glial fibri11ary acidic protein, an intermediate
filament protein expressed in the cytoplasm of astroglia, was identified
as another substrate for ROKct (33). Therefore, I will consider
substrate(s) of this kinase for neurite retraction in future studies. Until
now, we have obtained evidence that the activation of EP3 receptor,
coupling to Rho activation, did not affect the NGF-indllced MAP kinase
activation in the PC12 cells (data not shown), suggesting that the
activation of Rho or ROKct did not inhibit the NGF-induced sigRaling to
                           --15-
the Ras-MAP kinase pathway. To examine the direct effect of Rho or
ROKa on theNGF-induced differentiation, I am currently establishing
PC12 cell lines that express RhoAV14 or CD-ROKa under the control of
an inducible promoter.
As shown in Fig. 1-6, two fragments of ROKa, the Rho-binding
domain and the PH domain served as dominant negative forms of ROKa
in the EP3 receptor-mediated neurite retraction, as reported for the
formation of stress fibers and focal adhesion (28, 29). ROKa has been
shown to be translocated to peripheral membranes upon transfection
with RhoAV14 (21). Since PH domains are supposed to playa key role
in localization of molecules to the specific target regions in the
membranes, the PH domain of ROKa may localize this kinase at the
specified region in response to the EP3 receptor-induced activation of
Rho, and this translocation of ROKa to its target region seems to be
essential for inducing neurite retraction. On the other hand, RBD-
ROKa may block the interaction between endogenous Rho and ROKa.
We also showed that RhoAv14A37, a mutant at the effector region, lost
the ability to induce neurite retraction in the differentiated PC12 cells
(Fig~ 1-1, E and F, and Fig. 1-5). Indeed, RhoAV14 bound to the RBD-
ROKa but RhoAV14A37 did not (data not shown). This defect in binding
to ROKa seems to be the reason for the inability of RhoAv14A37 to
induce neurite retraction.
In this study, I have shown that ROKa is an essential component of
Rho-mediated neurite retraction in neuronal cells. Considering that
ROKa is enriched in the brain (28) and expressed in neurons (34),
R 0 K a may play a critical role in the regulation of neuronal cell
morphology and axonal guidance in the nervous system.
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2. Constitutively Active Gct12,Gct13, and Gctq Induce Rho-
dependent Neurite Retraction through Different Signaling
Pathways
Summary
    In neuronal cells, activation of a certain heterotrimeric G protein-
coupled receptor causes neurite retraction and cell rounding via small
GTPase Rho. However, the specific heterotrimeric G proteins that
mediate Rho-dependent neurite retraction and cell rounding have not yet
been identified. Here I investigated the effects of expression of
constitutively active Gct subunits on the morphology of differentiated
PC12 cells. Expression of GTPase-deficient Ga12, Gctl3, and Gctq, but
not Gcti2, caused neurite retraction and cell rounding in differentiated
PC12 cells. These morphological changes induced by Gct12, Gct13, and
Gaq were completely inhibited by C3 exoenzyme, which specifically
ADP-ribosyrates and inactivates Rho. A tyrosine kinase inhibitor
tyrphostin A25 blocked the neurite retraction and cell rounding induced
by Gct13 and Gaq. However, tyrphostin A25 failed to inhibit the Gct12-
induced neuronal morphological changes. On the other hand, inhibition
of protein kinase C or elimination of extracellular Ca2+ blocked the
neurite retraction and cell rounding induced by Gctq, whereas the
morphological effects of Gct12 and Gct13 did not require activation of
protein kinase C and extracellular Ca2+. These results demonstrate that
activation of Gct12, Gct13, and Gctq induces Rho-dependent




The activation of a certain heterotrimeric G protein-coupled
receptor, such as LPA, sphingosine-I-phosphate and thrombin
receptors, was shown to cause Rho-dependent neurite retraction in
several neuronal cell lines (17, 18,35). However, the heterotrimeric G
proteins, which are coupled to those receptors for induction of neurite
retraction, have not yet been identified. Previous studies demonstrated
that pertussis toxin (PT) did not inhibit receptor-mediated neurite
retraction (12, 36), indicating that this action was not mediated by Gi or
Go. Furthennore, the activation of Gs by cholera toxin or an elevation
of cAMP by forskolin failed to induce neurite retraction but rather
suppressed the receptor-mediated neurite retraction (31, 37), suggesting
that Gs activation was not linked to induction of neurite retraction.
The GI2 family of heterotrimeric G proteins, defined by GaI2 and
Gal3, is the most recent family to be identified using a homology-based
polymerase chain reaction (peR) strategy (38, Fig. 2-1). Although
immediate downstream effectors have not yet been identified, studies
with the constitutively active mutants of Gal2 and Gal3 have resulted in
the identification of several novel functions regulated by these Ga
subunits, including transformation of fibroblasts (39, 40), activation of
the c-Jun N-terminal kinase cascade (41-43), stimulation of stress fiber
formation and focal adhesion assembly (44,45), stimulation of the Na+-
H+ exchanger (46-48), the activation of phospholipase D (49), and the
induction of apoptosis (50). These studies also indicate that the Ras or
Rho family small GTPases appear to be involved in the downstream
responses regulated by Ga12 and Ga13.
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   To investigate the role of the G12 family and other Gct subunits in
neuronal cell morphology, I microiajected expression plasmids encoding
GTPase-deficient rnutants of Ga subunits into the nucleus of NGF-
differentiated PC12 cells bearing neurites. In this study, I have shown
that expression of constitutively active mutants of Ga12, Gct13, and Gorq
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Fig. 2-1.Mammalian heterotrimeric G protein ct subunits
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Results
Expression of Constitutively Active Ga Subunits in NGF-dijfferentiated
PC12 Cells
    To determine the role of the G12 family of heterotrimeric G
proteins in neuronal cell morphology, I expressed constitutively active
mutants of Gct12 and Gct13 in NGF-differentiated PC12 cells by nuclear






Figure 2-2. Neurite retraction and cell rounding induced by
constitutively active Gct12 and Gct13. -Expression plasmids (30 pg/mi) encoding
Gct12QL, Gct13QL, or the empty vector (Vector) were microiajected into the nucleus of
NGF-differentiated PC12 cells. Cells were photographed before (left panels) and 3 h
after (middle panels) microiojection under the microscope with phase contrast, or by
fluorescence of Texas red-coupled dextran co-microiojected with the expression vectors
(right panels). The arrows indicate irljected cells. The results shown are representative
of three independent experiments. The bar represents 50 pm.
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with a leucine in the G3 region of Ga subunit, which corresponds to
residue 229 in Ga12 or residue 226 in Ga13, has been shown to result in
a GTPase-deficient, constitutively active form of Ga subunit (51, 52).
As shown in Fig. 2-2, microinjection of expression plasmids (30 Jlg/ml)
encoding constitutively active Ga12 (GaI2Q229L; Ga12QL) and Gal3
(Gal3Q226L; Gal3QL) into the nucleus of NGF-differentiated PC12
cells caused retraction of their extended neurites and rounding of the
cell body within 3 h. Cells microinjected with the empty vector did not
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Figure 2-3. Neurite retraction and cell rounding induced by
constitutively active GUq and RhoA. Expression plasmids (30 Ilg/rnl) encoding
GUqQL, Ga'i2QL, or RhoAV14 were microinjected into the nucleus of NGF-
differentiated PCl2 cells. Cells were photographed before (left panels) and 3 h after
(middle panels) microinjection under the microscope with phase contrast, or by
fluorescence of Texas red-coupled dextran co-microinjected with the expression vectors
(right panels). The arrows indicate injected cells. The results shown are representative
of three independent experiments. The bar represents 50 Ilm.
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nonspecific effects due to nuclear microiajection itself. I also examined
the effects of GTPase-deficient mutants of Gctq (GctqQ209L; GctqQL)
and Gcti2 (Gcti2Q205L; Gcti2QL) on differentiated PC12 cell
morphology. As shown in Fig. 2-3, GctqQL, when expressed in
differentiated PC12 cells, mimicked Gct12QL and Gct13QL in induction
of neurite retraction and rounding of the cell body. In contrast,
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Figure 2-4. Effbct of C3 exoenzyme on neuronal morphological changes
induced by constitutively active Gct subunits. C3 exoenzyme (100 pg/ml)
was co-microiajected with expression plasmids (30 pg/mi) encoding Gct12QL,
Gct13QL, or GoeqQL into differentiated PC12 cells. Cells were photographed before
(left panels) and 3 h after (middle panels) microiajection under the microscope with
phase contrast, or by fluorescence of Texas red-coupled dextran co-microirijected with
the expression vectors (right panels). The arrows indicate iajected cells. The results
shown are representative of three independent experiments. The bar represents 50 ym.
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EiXifect of C3 Iixoenzyme on Constitutively Active Gor S"bunits-induced
Neuronal Morphological Changes
    Previous studies have shown that small GTPase Rho is reguired for
neurite retraction in response to a certain G protein-coupled receptor
agonist such as LPA (17, 18, 35). As shown in Fig. 2-3, microinjection
of expression plasmids encoding a constitutively active form of RheA,
RhoAV14, caused the retraction of neurites and rounding of the cell
body. These morphological changes induced by RhoAV14 were quite
similar to those induced by Ga12QL, Ga13QL, and GctqQL (Figs. 2-2
and 2-3). Therefore, to examine whether the neuronal morphological
changes induced by constitutively active forms of Gu subunits were
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Figure 2-5. Quantification of effect of C3 exoenzyme on neurite
retraction induced by constitutively active Gct subunits. Differentiated
PC12 cells were microinjected with expression piasmids (30 ptg/ml) encoding Ga12QL,
Gct13QL, GctqQL, Gai2QL, er the empty vector (Vector) in the absence (-C3) or the
presence (+C3) of 1oo pg/ml C3 exoenzyme. The percentages ofneurite-retracted cells
were determined 3 h after microinjection as described under "'Experimental
Procedures". Data are the means ± S.E. of triplicate experiments.
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plasmids into the cells with C3 exoenzyme. As shown in Figs. 2-4 and
2-5, co-microiajection of C3 exoenzyme (100 pg/ml) completely
blocked both neurite retraction and cell rounding induced by Gct12QL,
Gca3QL, and GctqQL. I also co-microinjected expression plasmids
encoding dominant negative form of RheA, RhoAN19, into the cells
with the censtitutively active mutants of Gct subunits. Coexpression of
RhoAN19 slightly blocked neurite retraction induced by Gct subunits but
was less effective than co-iajection of C3 exoenzyme (data not shown).
RhoAN19 would not be an effective inhibitor for complete suppression
of Gct subunits-induced morphological changes due to coexpression of
RhoAN19 and Gct subunits or requirement of large amount of RhoAN19
for the suppression,
EXfeet oj' a 71yrosine Kinase Inhibitor 71yrphostin A25 on Nearonal
Morphotogical Changes jinduced by Constitutively Active Ga Subunits
    A previous study showed that a tyrosine kinase inhibitor tyrphostin
A25 inhibited stress fiber formation stimulated by LPA but not by
microiajection of coRstitutively active Rho in quiescent Swiss 3T3
fibroblasts, indicating that a tyrosine kinase was involved in the LPA-
stimulated stress fiber formation acting upstreain of Rho (53).
Therefore, I examined the effect ef tyrphostin A25 on neuronal
morphological changes induced by constitutively active Gct subunits. As
shown in Figs. 2-6 and 2-7, treatment of differentiated cells with
tyrphostin A25 (150 pM) inhibited the Gct13QL- and GctqQL-induced
neurite retraction and cell rounding. In contrast, the neurite retraction
and cell rounding induced by Gct12QL were not infiuenced by this
tyrosine kinase inhibitor. Thus, tyrphostin A25 specifically inhibited
the signaling of Gor13QL and GctqQL. In addition, I examined the
effect of another tyrosine kinase inhibitor tyrphostin AG1478 on
-- 24 --
morphological changes induced by constitutively active Gct subunits.
Treatment of differentiated cells with tyrphostin AG1478 (10 pM) also
specifically inhibited the Gct13QL- and GctqQL-induced neurite
retraction and cell rounding, and Gct12QL-induced morphological
changes were not inhibited by this inhibitor (data not shown).
Gct12QL
Gct13QL









Figure 2-6. Effect of tyrphostin A25 on neuronal morphological
changes induced by constitutively active Gct subunits. After differentiated
PC12 cells had been microiojected with expression plasmids (30 pg/mi) encoding
Gct12QL, Geq3QL, GotqQL, they were incubated with tyrphostin A25 (150 pM) for 3
h. Cells were photographed before (left panels) and 3 h after (middle panels)
microirijection under the microscope with phase contrast, or by fluorescence of Texas
red-coupled dextran co-microirijected with the expression vectors (right panels). The
arrows indicate injected cells. The results shown are representative of three
























Figure 2-7. Quantification of effect of tyrphostin A25 on neurite
retraction induced by constitutively active Go. subunits. After differentiated
pe12 cells had been microinjected with expression plasmids (30 Ilg/ml) encoding
Ga12QL, GO,13QL, or GaqQL, they were incubated with vehicle (-Tyr) or 150 J.lM
tyrphostin A25 (+Tyr) for 3 h. The percentages of neurite-retracted cells were
determined 3 h after microinjection as described under "Experimental Procedures",
Data are the means ± S.E. of triplicate experiments.
Effects of Protein Kinase C Inhibition and Elimination of Extracellular
Ca2+ on Neuronal Morphological Changes Induced by Constitutively
Active Ga Subunits
A number of the cellular responses caused by activation of Gaq
have been shown to be mediated by activation of protein kinase C (PKC)
or elevation of intracellular Ca2+ concentration. Therefore, I examined
whether activation of PKC was required for neuronal morphological
changes induced by constitutively active Gaq and GcQ2/Ga13. Exposing
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PC12 cells to 12-0-tetradecanoylphorbol-13-acetate (TPA) for more
than 24 h has been reported to induce down-regulation of PKC (54). As
shown in Figs. 2-8 and 2-10, down-regulation of endogenous PKC by
24-h exposure to 1 pM TPA diminished the amount of neurite-retracted
cells caused by GctqQL, whereas the Gct12QL- and Gct13QL-induced
morphological changes were not significantly altered by PKC depletion
from cells. Similar results were obtained in the treatment of cells with
the PKC inhibitor Ro31-8220 (300 nM) (Fig. 2-10). These results
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Figure 2-8. Effect of depletion of intracellular PKC on neuronal
morphological changes induced by constitutively active Gct subunits.
Differentiated PC12 cells, which had been pretreated with TPA (1 pM) for 24 h, were
microiojected with expression plasmids (30 pg/ml) encoding Gct12QL, Gct13QL,
GctqQL. Cells were photographed before (left panels) and 3 h after (middle panels)
microirijection under the microscope with phase contrast, or by fiuorescence of Texas
red-coupled dextran co-microiajected with the expression vectors (right panels). The
arrows indicate irijected cells. The results shown are representative of three
independent experiments. The bar represents 50 pm.
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indicate that inhibition of PKC activity specifically interferes with the
signaling pathway of Gctq for neurite retraction and cell rounding.
    Next I examined the role of Ca2+ signaling in neuronal
morphological changes induced by activated Gct subunits.
Differentiated PC12 cells were incubated in a Ca2+-free medium in the
presence of 2 mh EGTA during expression of Gct subunits. Under
these conditions, expression of GctqQL failed to induce neurite
retraction and cell rounding. In contrast, neuronal morphological
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Figure 2-9. Ethct of elimination of'extracellular Ca2+ on neuronal
morphological changes induced by constitutively active Gct subunits.
After differentiated PC12 cells had been microiajected with expression plasmids (30
pg/ml) encoding Gct12QL, Gct13QL, GctqQL, they were incubated in the Ca2+-free
medium containing EGTA (2 mM) for 3 h. Cells were photographed before (left
panels) and 3 h after (middle panels) microiajection under the microscope with phase
contrast, or by fluorescence of Texas red-coupled dextran.co-microiajected with the
expression vectors (right panels). The arrows indicate irijected cells. The results
shown are representative ofthree independent experiments. The bar represents 50 lrm.
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changes induced by Gal2QL and Ga13QL were normally occurred in a
Ca2+-free medium with EGTA (Figs. 2-9 and 2-10). These results
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Figure 2-10. Qllantification of effects of inhibition of PKC and
elimination of extracellular Ca2+ on neurite retraction indllced by
constitutively active Gct subunits. After differentiated PC12 cells had been
microinjected with expression plasmids (30 pg/ml) encoding Gcti2QL, Gpti3QL, or
GotqQL, they were incubated in the absence (Control) or the presence of 3oo nM Ro3 1-
8220 (+Ro31-8220), or in the Ca2'-free medium containing 2 mM EGTA (Ca2+--free)
fbr 3 h. Or expression plasmids were microiajected into differentiated cells which had
been treated with l pM TPA for 24 h before microinjection to induce down-regulation
of endogenous PKC (PKC-depleted). The percentages of neurite-retracted cells were
determined 3 h after microinjection as described under "Experimentai Procedures".
Data are the means ± S.E. of triplicate expenments.
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Discussion
    Activation of a certain G protein-coupled receptor has been
reported to induce Rho-dependent neurite retraction and cell rounding
in neuronal cell lines (17, 18, 31, 35). Here I have demonstrated that
constitutively active forms of Gct12, Gct13, and Gctq, but not Gcti2, can
trigger neurite retraction and cell rounding in NGF-differentiated PC12
cells. These morphological changes were similar to those induced by
constitutively active RhoA, RhoAV14 (Fig. 2-3), and C3 exoenzyme,
which specifically ADP-ribosyrates and inactivates Rho (15, 16),
completely inhibited both neurite retraction and cell rounding induced
by Gor12QL, Gor13QL, and GctqQL (Figs. 2-4 and 2-5), indicating that
activation of Gct12, Gor13, and Gctq induces neurite retraction and cell
rounding through a Rho-dependent signaling pathway in differentiated
PC12 cells.
    Gct12 and Gct13, the members of the G12 class of heterotrimeric G
protein, show a 67% amino acid identity with each other, and often
c.ause similar responses in various cell types, including transformation
of fibroblasts, activation of the c-Jun N-terminal kinase cascade, and
stimulation of stress fiber formation and focal adhesion assembly (55).
I have also shown that both Ga12 and Gct13 can trigger Rho-dependent
neurite retraction and cell rounding. These findings suggest that Gct12
and Gct13 may interact with a common effector. In this study, however,
the tyrosine kinase inhibitor tyrphostin A25 blocked the Gct13QL-
induced neurite retraction and cell rounding, whereas the Gct12QL-
induced morphological changes were not influenced by this tyrosine
knase inhibitor (Figs. 2-6 and 2-7), indicating that a tyrphostin-sensitive
tyrosine kinase was involved in the signaring of Gct13 but not in that of
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Ga12. This finding strongly suggests that Ga12 and Gal3 use different
signaling pathways to regulate neuronal cell morphology. The
differences in the sensitivity to tyrphostin between Ga12 and Ga13 were
also shown in the signaling of Ga12- and Gal3-stimulated stress fiber
formation and focal adhesion assembly in Swiss 3T3 fibroblasts (45).
Furthermore, it was previously reported that Ga12 and Gal3 stimulated
Na+-H+ exchangers through different mechanisms in COS-7 cells (56,
57). Therefore, it is likely that Gcq 2 and Ga 13 activate different
effectors to regulate their cellular functions.
Activation of Gaq can stimulate the family of phospholipase C
(PLC)-~, which results in stimulation of PKC activity and elevation of
intracellular Ca2+ concentration. In this study, both depletion 0 f
endogenous PKC by TPA and the PKC inhibitor R031-8220 specifically
diminished the amount of neurite-retracted cells induced by GaqQL,
whereas the Ga12QL- and Gal3QL-induced morphological changes
were not influenced (Figs. 2-8 and 2-10). In addition, elimination of
extracellular Ca2+ also inhibited the effects of GaqQL but not those of
Ga12QL and Ga13QL (Figs. 2-9 and 2-10). It has been known that
inositol 1,4,5-trisphosphate and inositol 1,3,4,5-tetrakisphosphate,
products of PLC activation pathways, activate Ca2+-permeable channels
in plasma membranes (58, 59). Recently, Gaq was reported to activate
inositol 1,4,5-trisphosphate-operated Ca2+-permeable channels (60).
The requirement of extracellular Ca2+ for the Gaq-induced
morphological changes could be interpreted by this Gaq-mediated Ca2+-
permeable channel activation. Therefore, both PKC activation and Ca2+
influx are essential elements in the signaling of Gaq upstream of Rho. I
also examined the involvement of PLC in the GaqQL signaling using a
PLC inhibitor U-73122, but this compound was cytotoxic for
differentiated PC12 cells, and treatment with U-73122 alone caused cell
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detachment. Interestingly, both PKC activity and Ca2+ infiux as a result
of PLC activation appeared to be required for LPA-induced neurite
retraction in NGF-ditiferentiated PC12 cells (18). Therefore, it is 1ikely
that a Gq-coupled LPA receptor stimulates PLC activity and resultant
activation of PKC and Ca2+ influx induces Rho-dependent neurite
retraction in PCI2 cells.
    Interestingly, the GaqQL-induced neurite retraction and cell
rounding were also blocked by treatment of cells with the tyrosine
kinase inhibitor tyrphostin A25 (Figs. 2-6 and 2-7), indicating that a
tyrphostin-sensitive tyrosine kinase is involved in the signaling from
Gaq to Rho. My present study did not show whether this tyrphostin-
sensitive tyrosine kinase acts upstream or downstream of Ca2+ and PKC
in the signaling from Gctq to Rho. Since activation of Gctq can directly
stimulate PLC which results in.stimulation ef PKC activity and elevation
of intracellular Ca2+ concentration, this tyrphostin-sensitive tyrosine
kinase may act downstream of Ca2+ and PKC. Recently, a novel
RoRreceptor tyrosine kinase PYK2 has been shown to mediate Gq-
coupled receptor-stimulated activation of MAP kinase cascade in PC12
cells, and the activity of this tyrosine kinase appears to be regulated by
the elevation of the intracellular Ca2+ concentration as well as by PKC
activation (61). Therefore, PYK2 can be speculated to be a candidate
for the tyrosine kinase, which links the signal of Gctq to Rho for the
induction of neurite retraction and cell rounding. A tyrphostin-sensitive
tyrosine kinase was of course involved in the signaling of Gct13 to Rho.
However, in contrast to Gctq,Gct13 did not require either PKC
activation or Ca2+ influx. Two potential explanations for the difference
between signaling pathways of Gct13 and Gctq can be presented. One
explanation is that an identical tyrosine kinase mediates the signals of
Ga13 and Gctq to Rho, but the pathways of both or subunits to activate
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the tyrosine kinase are different; Gag activates the kinase through PKC
and Ca2+ influx while Ga13 activates the kinase independent of PKC.
The other explanation is that different tyrosine kinases are involved in
the pathways of both a subunits. Further investigations are necessary to
understand the signaling pathways from Ga subunits to Rho in neuronal
cells.
Expression of a GTPase-deficient form of Gag in undifferentiated
PC 12 cells was recently shown to induce neurite outgrowth during 2-3
weeks using the retrovirus-mediated infection procedure (62). In
contrast, my results showed that expression of GagQL in NGF-
differentiated PC12 cells triggered neurite retraction within 3 h after
microinjection. Therefore, these opposite effects of Gag on the
regulation of neurites may be due to different condition of cells in
differentiation or different time scale for examination of morphological
effects.
The data presented here demonstrated that constitutively active
mutants of Ga12, Ga13, and Gag can induce neurite retraction and cell
rounding through different signaling pathways which, however, finally
converge at activation of Rho. Rho, like other small GTPases, functions
as a molecular switch; it is active in its GTP-bound state and inactive in
its GDP-bound state. Upstream activation of the cycle is mediated by
GEFs, which promote the exchange of GDP for GTP (Fig. 0-1). A
number of putative GEFs for Rho and other Rho family GTPases have
been identified, and some of these demonstrate Rho-specific GEF
activity in vitro, including Lbc, Lfc, and Lsc (6, 63-65). In addition,
they appear to be expressed in the same cell type (64). Therefore, one
possibility for the existence of multiple GEFs for Rho in the same cell
type may be related to the existence of different signaling pathways
from Ga subunits to activation of Rho.
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Recent studies have shown the involvement of the Rho family of
small OTPases in the regulation of neurite outgrowth in primary
neurons (66, 67). In embryonic chick dorsal root ganglion, inhibition
of Rho with C3 exoenzyme stimulated the outgrowth of neurites (66),
suggesting that activation of Rho suppresses neurite outgrowth in
primary neurons. Therefore, Go: 12, Go: 13, and Gaq may play a
negative regulator for neurite outgrowth through activation of Rho in
primary neurons.
In this study, I have shown that activation of 00:12, GO:13, and GO:q
can trigger Rho-dependent neurite retraction and cell rounding in
differentiated PC 12 cells through different signaling pathways. This
study will contribute to the understanding of the signal transduction
between heterotrimeric G protein-coupled receptors and Rho in
neuronal cells.
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3. Prostaglandin EP3 Receptor Induces Neurite Retraction
    through Small GTPase Rho
Summary
    Prostaglandin EP3 receptor is widely distributed in the nervous
system and is specifically Iocalized to neurons, suggesting that EP3
receptor plays important roles in the nervous system. I established a
PC12 cell line which stably expresses the EP3B receptor isoform
isolated from bovine adrenal chromaffin cells and examined the effect
of agonist stimulation on the neuronal morphology of the PC12 cells. In
the differentiated cells, M&B28767, an EP3 agonist, caused neurite
retraction in a PT-insensitive manner. Clostridium botulinumC3
exoenzyme completely inhibited the EP3 receptor-induced neurite
retraction when microinjected into the cells, indicating that the
morphological effect of the EP3 receptor is depeRdent on Rho activity.
The EP3 receptor-mediated neurite retraction occurred normally in the
PKC-down-regulated cells. Similar to the Gct13QL-induced neurite
retraction, tyrphostin A25, a tyrosine kinase inhibitor, blocked neurite
retraction induced by activation of the EP3 receptor. These results




Prostaglandin (PG) E2 is synthesized via cyclooxygenase pathway
from arachidonic acid by a variety of cells in response to various
physiological or pathological stimuli (Fig. 3-1). PGE2 is one of the
major POs synthesized in the nervous system (68), and it has several
important functions in the nervous system, such as generation of fever
(69, 70), regulation of luteinizing hormone-releasing hormone secretion
(71), pain modulation (72), and regulation of neurotransmitter release
(73,74). Although cyclooxygenase products including PGE2 have been
suggested to be involved in regulation of memory consolidation (75),
the biological significance of POE2 in synaptic plasticity is not yet
understood.
POE2 acts on cell surface receptors to exert its actions (76). PGE
receptors are pharmacologically divided into four subtypes, EPl, EP2,
EP3 and EP4, on the basis of their responses to various agonists and
antagonists (77, 78). Among these subtypes, EP3 receptor has been
most well characterized and has been suggested to be involved in such
PGE2 actions as contraction of the uterus (79), inhibition of gastric acid
secretion (80), modulation of the neurotransmitter release (81), lipolysis
in adipose tissue (82), and sodium and water reabsorption in the kidney
tubules (83). Although the well-known EP3 receptor-mediated actions,
mentioned above, are believed to be mediated through inhibition of
adenylate cyclase by activation of Gi, coupling of EP3 receptors to other
signal transduction pathways has been suggested (84, 85). The four
subtypes of mouse POE receptors have been cloned and it is
demonstrated that they are heterotrimeric G protein-coupled rhodopsin-
type receptors (86-89). Among these subtypes, the EP3 receptor was
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most abundant in the brain and was specifically localized to neurons (90,
91).
    To assess the role of the EP3 receptors in the nervous system, I
introduced the cDNA for the EP3B receptor, one of the EP3 receptor
isoforms isolated from bovine adrenal medulla (85), into PC12 cells. In
this study, I have shown that the activation of the EP3 receptor causes
neurite retraction through small GTPase Rho and that a tyrosine kinase
is involved in the EP3 receptor-mediated neurite retraction acting
upstream of Rho.
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EiZ7lact qfM&B28767 on Morphology of the EP3 Receptor-Expressing
PCI2 Cells, De(7i7rentiated with NGF
    To assess the role of EP3 receptors in neuronal morphology, I
established PC12 cells, which stably expressed the EP3B receptor (151
ftnoVmg protein). I initially examined the coupling.of the EP3 receptor
to the classical signal transduction pathways, the adenylate cyclase and





Figure 3-2. M&B28767-induced neurite retraction in EP3B receptor-
expressing PC12 cells. After the cells had been differentiated fbr 5 d with NGF, 1
pM M&B28767 was added to the cells and they were photographed at the times
indicated as described under "Experimental Procedures". The result shown is
representative of three independent experiments that yielded similar results. Bar
represents 50 pm.
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adenylate cyclase activity through a PT-sensitive heterotrimeric G
protein, but the receptor could not stimulate adenylate cyclase,
phosphatidylinositol hydrolysis, or Ca2+ mobilization (data not shown),
suggesting that the EP3 receptor is coupled to Gi, but not to Gs or Gq.
I next examined the effect of M&B28767, a specific EP3 agonist, on the
neuronal morphology of the EP3 receptor-expressing PC12 cells. As
shown in Fig. 3-2, treatment of the cells with NGF induced neurite
outgrowth. Addition of M&B28767 caused a dramatic morphological
change in the NGF-differentiated PC12 cells. Within 10 min of the
addition of the agonist neurites began to retract, and within 30 min,
most neurites had retracted completely. Fig. 3-3A shows the time
course of the effect of the agonist on neurite Iength. The neurite length
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Figure 3-3. The time ceurse and concentration dependency of
M&B28767-induced neurite retraction. (A) Time course. After cells had been
differentiated with NGF for 5 d, 1 pM M&B28767 was added. The average neurite
length at the times indicated was measured as described in the Experimenral Procedures.
Data are means ± S.E. of tripiicate experiments. (B) Concentration dependency. The
differentiated cells were exposed to the indicated concentrations of M&B28767 for 60
min. The pe;centage of neurite retracted cells was determined as described in the
Experimental Procedures. Data are means ± S.E. of triplicate experiments,
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retraction was not dependent on the concentration of the agonist (data
not shown). M&B28767 concentration-dependently increased the
population of neurite retracted cells, and more than 90% of the total
cells responded to 1 pM M&B28767 (Fig. 3-3B). However, a few cells
resisted even high concentrations of the agonist. M&B28767-induced
neurite retraction was not seen for more than 60 min in the
untransfected cells (data not shown).
    The EP3 receptor inhibited adenylate cyclase via a PT-sensitive
heterotrimeric G protein. However, pretreating the EP3 receptor-
expressing cells with PT for 12 h did not affect M&B28767-induced
ewma
Figure 3-4. Effect of PT on M&B28767-induced neurite retraction. (A)
Cells were differentiated with NGF for 5 d. (B) Cells in A were exposed to 1 pM
M&B28767 for 60 min. (C) NGF-differentiated cells were treated with 20 ng/mi PT
for 12 h. (D) Cells in C were exposed to 1 pM M&B28767 for 60 min, The results
shown are representative of three independent experiments that yielded simi1ar results.
Bar represents 50 pm.
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neurite retraction (Fig. 3-4 and 3-8), indicating that ghe EP3 receptor-
mediated neurite retraction was not mediated through a PT-sensitive G
protem.
    I further examined the effect of protein kinase A (PKA) activation
on the EP3 receptor-mediated neurite retraction. As shown in Fig. 3-5,
whereas dibutyryl cAMP (Bt2cAMP) did not affect the morphology of
the differentiated cells, it strongly prevented M&B28767-induced
neurite retraction. Fig. 3-8 shows the quantitative examination of the
effect of Bt2cAMP. It decreased the percentage of neurite-retracted




Figure 3-5. Effect of Bt2cAMP on M&B28767-induced neurite
retraction. (A) Cells were differentiated with NGF for 5 d. (B) Cells in A vvere
exposed to 1 pM M&B28767 for 60 min. (C) Differentiated cells were pretreated with
5oo pM Bt2cAMP for 15 min. (D) Cells in C were exposed to 1 pM M&B28767 for
60 min. The results shown are representative of three independent experiments that
yielded simi1ar results. Bar represents 50 pm.
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indicate that the activation of PKA suppresses EP3
neurite retraction.
receptor-mediat d
EX7lact of C3 lixoenayme on M&B28767-induced Neurite Retraction
    A smal1 G protein, Rho, appears to be required for the retraction
of neurites (17). To evaluate the participation of Rho in the EP3
receptor-mediated neurite retraction, the cells were microiajected with
C botulinum C3 exoenzyme, which specifically ADP-ribosylates Rho
and suppresses the actions of Rho (15, 16). As shown in Fig. 3-6,
M&B28767-induced neurite retraction was completely inhibited in a cell
microiajected with C3 exoenzyme, whereas M&B28767-induced
morphological change was not inhibited in a cell microiajected with the
buffer alone (data not shown), indicating that microiajection itself did
not inhibit neurite retraction. These results demonstrate that the EP3
receptor-mediated neurite retraction is required for the activation of
Rho.
Figure 3-6. Effect of C3 exoenzyme on M&B28767-induced neurite
retraction. Differentiated cells were miCroiajected with 1oo pg/ml C3 (A) and then
stimulated with 1 pm M&B28767 for 60 min (B). M&B28767 was added 30 min after
irijection. The arrows indicate iajected cells. The results shown are representative of
three independent experiments. At least 20 cells were microinjected in each experiment
for C3 exoenzyme and the control buffer, and al1 cells microiojected gave the described
response. Bar represents 50 lrm.
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EXjFlact of Depletion of Intracellular PKC on M&B28767-induced
Aleurite Retraction
    As shown in Chapter 2, constitutively active Gctq induces Rho-
dependent neurite retraction and cell rounding, and these morphological
changes are required for activation of PKC. Therefore, I examined
whether the morphological action of the EP3 receptor was mediated by
the activation of PKC. Even though the cells had been exposed to 1 pM
TPA during differentiation and endogenous PKC had been down-
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Figure 3-7. Ethct of depletion of intracellular PKC on M&B28767-
induced neurite retraction. (A) Cells were differentiated with NGF for 5 d. (B)
Cells in A were exposed to 1 pM M&B28767 for 60 min. (C) Cells were differentiated
with NGF for 5 d in the presence of 1 pM TPA. (D) Cells in C were exposed to 1 pM
M&B28767 for 60 min. The results shown are representative of three independent
experiments that yielded simi1ar results. Bar represents 50 pm.
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retraction induced by M&B28767 was not affected (Fig. 3-7 and 3-8).
These results indicate that EP3 receptor-mediated morphological change
does not involve the activation of PKC.
Effect of Tyrphostin A25 on M &B28767- or RhoA-Induced Neurite
Retraction
As shown in Chapter 2, constitutively active GU13-induced neurite
retraction was inhibited by a tyrosine kinase inhibitor tyrphostin A25.
Therefore, I next examined whether tyrphostin A25 blocked
M&B28767-induced neurite retraction in the NGF-differentiated PC12














Figure 3-8. Quantification of effects of various reagents on
M&B28767-induced neurite retraction. The percentages of neurite-retracted
cells was determined as described under "Experimental Procedures", Data are means ±
S.B. of triplicate experiments.
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in response to 1 pM M&B28767 within 30 min (Fig. 3-9, A and B). In
contrast, pretreatment of the cells with 300 pM tyrphostin A25 for 15
min blocked M&B28767-induced neurite retraction (Fig. 3-9, C and D).
Fig. 3-11 shows the quantitative examination of the effect of tyrphostin
A25. It decreased the percentage of the neurite-retracted cells in
response to M&B28767 from 97.0 to 13.7%. The cells treated with
tyrphostin A25 alone caused no morphological change for at least 60
min (data not shown). These results indicate that a tyrphostin A25-
,ma
Figure 3-9. Effect of tyrphostin A25 on.neurite retraction induced by
M&B28767. The cells differentiated with NGF for 3 days were pretreated with
vehicle (A and B) or 3oo pM tyrphostin A25 (C and D) for 15 min. Then the cells were
photographed before (A and C) and 30 min after (B and D) the addition of 1 pM
M&B28767. The results shown are representative of three independent experiments.




sensitive tyrosine kinase was involved in the EP3 receptor･-mediated
neurite retraction.
    To determine whether this tyrphostin A25-sensitive tyrosine kinase
functioned upstream or downstream of Rho, I next microiajected
constitutively active RhoA, RhoAV14, into the cytoplasm of the
differentiated PC12 cells. More than 70% of the cells microiojected
with 2 mglml of RhoAV14 caused neurite retraction and cell rounding
within 30 min. However, pretreatment of the cells with 300 pM
Figure 3-10. Effk)ct of tyrphostin-A25 on neurite retraction induced by
RhoAV14. The cells differentiated with NGF for 3 days were pretreated with vehicle
(A and B) or 3oo pM tyrphostin A25 (C and D) for 15 min. Then the cells were
photographed before (A and C) and 30 min after (B and D) microirijection of 2 mg/mi
RhoAV14. The arrows indicate iojected cells. The results shown are representative of
three independent experiments. The bar represents 50 pm.
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j
tyrphostin A25 for 15 min did not blocked neurite retraction induced by
microinjection of RhoAV 14 (Fig. 3-10, and Fig. 3-11). These results
indicate that a tyrphostin A25-sensitive tyrosine kinase is not involved in
























Figure 3-11. Quantification of effect of tyrphostin A25 on neurite
retraction induced by M&B28767 and RhoAV14. The cells differentiated with
NGF for 3 days were pretreated with vehicle (-Tyr) or 300 ~M tyrphostin A25 (+Tyr)
for 15 min. Then the cells were exposed to 1 ~M M&B28767 or microinjected with 2
mg/ml RhoAV14. The percentages of neurite-retracted cells were determined 30 min
after the addition of the agonist or microinjection of RhoAV 14, as described under
"Experimental Procedures". Data are the mean ± S.E. of triplicate experiments.
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Discussion
Infonnation on the function of EP3 receptors in the nervous system
is scarce, although several findings have been reported, for example,
they inhibit neurotransmitter release and have hyperalgesic effects (92,
93). In this study, I described a new possible function of EP3 receptors,
modulation of a neuronal morphological change through a novel
pathway distinct from adenylate cyclase inhibition or PKC activation.
In EP3 receptor-expressing PCl2 cells differentiated with NGF,
M&B28767 induced neurite retraction. However, no morphological
change was caused by the agonist in untransfected cells, indicating that
M&B28767-induced neurite retraction is mediated by EP3 receptor.
Growing evidence suggests that Rho plays a key role in the
regulation of the actin cytoskeleton. The functions of Rho have been
explored using the C3 exoenzyme, which ADP-ribosylates and
inactivates Rho protein (15, 16). Many studies using C3 exoenzyme
demonstrated that Rho is involved in the control of cell shape, adhesion,
and motility by regulating the actin cytoskeleton in fibroblasts (3), and it
is also involved in neurite retraction in neuronal cells (17). Since
microinjection into the EP3 receptor-expressing cells with the C3
exoenzyme completely inhibited M&B28767-induced neurite retraction
(Fig. 3-6), Rho was shown to be an essential element in the EP3
receptor-mediated neurite retraction.
Among classical second messenger pathways, EP3 receptor is
coupled to adenylate cyclase inhibition through Gi in pel2 cells, but the
receptor stimulates neither adenylate cyclase nor PLC, indicating that
EP3 receptor is exclusively coupled to Oi. However, neurite retraction
mediated by this receptor was not suppressed by PT treatment (Figs. 3-4
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and 3-8), indicating that Gi is not involved in the EP3 receptor-mediated
neurite retraction. In Chapter 2, expression of constitutively active
mutants of Gor12, Ga13, and Gctq induced Rho-dependent neurite
retractien and cell rounding in NGF-differentiated PC12 cells. Among
these Gct subunits, Gct13- and 6ctq-induced neuronal morphological
changes were blocked by tyrphostin A25, whereas the morphological
changes by Ga12 were not influenced by this tyrosine kinase inhibitor.
Because tyrphostin A25 blocked the EP3 receptor-mediated neurite
retraction, Gct12 does not appear to mediate the signaling from EP3
receptor to Rho activation. Neuronal morphological changes by Gctq
also required activation of PKC and Ca2+ infiux. However, activation
of the EP3 receptor did not increase intracellular Ca2+ concentration in
the PC12 cells, and the neuronal morphological changes by the EP3
receptor were not blocked by inhibition of PKC activity (Figs. 2-7 and
2-8) or elimination of extracellular Ca2+ (data not shown). Taken
together, these results suggest that Gct13 may be involved in the EP3
receptor-mediated Rho activation leading to neurite retraction in the
differentiated PC12 cells.
    I examined the regulation of the EP3 receptor-mediated neurite
retraction by PKA, and revealed that activation of PKA inhibited EP3
receptor-mediated neurite retraction, indicating that PKA is a negative
regulator. As the potential PKA phosphorylation site is located in the
first cytoplasmic loop of the EP3 receptor, it is possible that PKA
phosphorylates the EP3 receptor. The phosphorylation of this site by
PKA may stop the EP3 receptor-mediated signaling. The second
possible site of the action of PKA is on a downstream component. LPA-
induced Beurite retraction was receRtly reported to be prevented by
pretreatment with Bt2cAMP in PC12 cells (37). Furthermore, it was
recently reported that PKA directly phosphorylated Rhe and this
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phosphorylation resulted in termination of Rho signaling (94). As LPA
and EP3 receptors use different pathways to activate Rho, PKA may
block Rho-mediated morphological regulation by phosphorylating Rho
in PC12 cells.
From this study, we propose new possible functions of PGE2 acting
through EP3 receptors in the nervous system. EP3 receptors have been
shown to be expressed in a variety of neurons in the brain (90, 91), and
neurons in the dorsal root ganglion (95). PGE2 is nonnally produced in
the brain, and its production is dramatically stimulated by brain injuries,
such as concussion, trauma, and asphyxia (96-99). When the brain is
injured, newly synthesized PGE2 may retract the neurites of EP3
receptor-expressing neurons and reorganize damaged neuronal
connections. In addition, the levels of PGE2 are also increased in the
brain by synaptic activity or during development (100). Furthermore,
cyclooxygenase, a rate-limiting enzyme in PO synthesis, has been
reported to be markedly induced by seizures or N-methyl-D-aspartate-
dependent synaptic activity, especially in the cortex and hippocampus
(101), in which EP3 receptors are highly expressed (90). PGE2 may be
.involved in refining and remodeling the initial neuronal connections
through EP3 receptors.
In the present study, I have shown that EP3 receptor elicits neurite
retraction in a Rho-dependent fashion. This study will contribute not
only to the understanding of neuronal PGE2 function, but it will also
help to elucidate the molecular mechanisms of signal transduction
pathways between heterotrimeric G protein-coupled receptors and Rho.
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CONCLUSION




p160 RhoA-binding kinase ROKct,atarget for RhoA acts
downstream of Rho to induce neurite retraction in PC12 cells.
Activation of Gor12, Gorl3, and Gorq induces Rho-dependent neurite
retraction in PC12 cells through different signaling pathways.
Prostaglandin EP3 receptor is coupled to Gct13 causing neurite
retraction through a RholRho-associated kinase-dependent pathway
in PC12 cells.
    The present study will not only contribute to the understanding of
the signal transduction pathway involving Rho in neuronal cells, but will
also help to elucidate the molecular mechanisms for neuritogenesis and
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   M&B28767 was a generous gift from Dr. M. P. L. Caton of
Rhone-Poulene Ltd. NGF 2.5S was purchased from Promega
Corporation, and Ctostridium botulinumC3 exoenzyme was from
Seikagaku Kogyo. Texas red-coupled dextran was from Molecular
Probes, tyrphostin A25 and tyrphostin AG1478 were from Calbiochem,
Ro31-8220 was from Nacalai Tesque, Bt2cAMP was from Sigma, and
TPA was from Funakoshi Pharmaceuticals. The sources of the other
materials are shown in the text.
Iixpression and Purijication ofRecombinant Proteins
   The coding region of human RhoA was generated by reverse
transcription-PCR from HeLa cells using primers 5'-CTGGACTCGAA
TTCGTTGCCTGAGCAATGG-3' and 5'-GCAAGATGAATTCTGATT
TGTAATCTTAGG-3`. The PCR product was digested with EcoRI ,
cloned into the pBluescript KS(+), and completely sequenced. cDNAs
for RhoAVi4 and RhoAVi4A37 were generated by PCR-mediated
mutageneis (102), subcloned into the BamHI/EcoRI sites of pGEX-4T-2
vector, and sequenced, Recombinant RhoAVi4 and RhoAVi4A37 were
expressed as GST fusion proteins in E.coli, and purified on glutathione-
Sepharose beads according to the method of Self, A. J. and Hall, A.
(103). The sequence encoding ROKct containing the catalytic domain
(CD-ROKct, amino acids 1-543), the Rho-binding domain (RBD-ROKct,
amino acids 932-1065), and the PH domain (PHD-ROKct, amino acids
1116-1379) were generated by reverse transcription-PCR from PC12
cells, using primers 5'-ATGAGCGGATCCCCGCCGACGGGGAAA-3'
and 5'-ACCTTCTGAATTCATATCTGAGAGCTCTGG-3' for CD-
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ROKct, 5'-GACGGATCCAAAGAGAAGATCATGAAAGAGC-3' and
5'-GTTGTGTGAATTCTTAACGTTCAG-3' for RBD-ROKa, and 5'-
TCGCAGGGATCCGCCTTGCATATTGG-3' and 5'-TCTTGTGGATG
GAAGAATTCGATCACCTTC-3' for PHD-ROKor, respectively. The
kinase-deficient mutant of CD-ROKct (CD-ROKctKii2G) was generated
by PCR-mediated mutageneis. All PCR products for each domain of
ROKa were cloned into the pCR2.1 vector and sequenced completely.
The PCR products for RBD-ROKor and PHD-ROKct were subcloned
into the BamHIIEcoRI sites of pGEX-4T-2 vector, and recombinant
proteins were expressed as GST fusion proteins in E.coli and purified
on glutathione-Sepharose beads. The PCR products for CD-ROKct and
CD-ROKctKii2G were subcloned into the BamHIIEcoRI sites of pAcG2T
vector, and recombinant proteins were expressed as GST fusion proteins
in Sf9 cells with BaculoGoldTM system (PharMingen) and purified on
glutathione-Sepharose beads according to the method of Matsui, T. et al.
(23). All recombinant proteins were dialyzed with an iajection buffer
(10 mM Tris-HCI, pH 7.6, 150 mM NaCl, 2 mM MgC12, and O.1 mM
dithiothreitol) at 4 OC overnight for microinjection. Protein
concentration was determined by comparing with bovine serum albumin
standards after electrophoresis on a SDS-polyacrylamide gel and
staining with Coomassie Brilliant Blue. Purified proteins showed only
ene band on Coomassie-stained gel.
Construction ofMammalian E)tpression Plasmids
    Wild type mouse Gct12 and Gct13 were generous gifts from Dr. M.
I. SimoR (California Institute of Technology). Wild type rat Gai2 was
kindly provided from Dr. T. Katada (Tokyo University). Mammalian
expression vector pEF-BOS was kindly provided from Dr. S. Nagata
(Osaka University). Wild type mouse Gctq was generated by reverse
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transcription-PCR from mouse brain using primers 5'-GAGGCACTTC
GGAAGAATGA-3' and 5'-AAGAACCAGTTTCTGGGAGG-3', and
the PCR product was cloned into the pCR2.1 vector and sequenced
completely. The cDNAs of the constitutively active mutants of Ga12
(Gcti2Q229L; Gori2QL), Gai3 (Gori3Q226L; Gcti3QL), Gaq
(GaqQ209L; GctqQL), Gori2 (Gcti2Q205L; Gcti2QL), and the cDNA of
RhoAN19 were generated by PCR-mediated mutagenesis (102), and
sequenced completely. The cDNAs of constitutively active mutants of
Gor subunits were inserted into the pcDNA3 expression vector
(Invitrogen), and the cDNAs of RhoAV14 and RhoAN19 vvere inserted
into pEF-BOS.
Cell Culture and Microinjection
    PC12 cells were cultured in Dulbecco's modified Eagle's medium
(DMEM) containing 5% fetal bovine serum, 10% horse serum, 4 mM
glutamine, 100 unitslml penicillin, and O.2 mg/ml streptomycin under
humidified conditions in 95% air and 5% C02 at 37 OC. To obtain EP3
receptor-expressing PC12 cells, cDNA encoding the EP3B receptor was
inserted into the expression vector, pcDNA3, and the plasmid
constructed was transfected into PC12 cells by lipofection (104). Stable
transformants were cloned by selection with 500 pg!ml of G418 (Gibco
laboratories life technologies, Inc.). For microinjection, cells were
seeded at a density 2 x 104 onto poly-D-lysine (Sigma)-coated 35 mm
dishes, which were marked with a cross to facilitate the localization of
iajected cells. Microinjection was performed using an IMM-188
microinjection apparatus (Narishige). After cells had been
differentiated in serum-free DMEM containing 50 ng/ml NGF for 3 or
4 days, 30 pg/ml of the indicated plasmids were microiajected into the
nucleus with 1 mglml Texas red-coupled dextran to visualize iajected
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cells, or 2 mg/ml of recombinant proteins were microinjected into the
cytoplasm. During microinjection, differentiated cells were maintained
in Hepes-buffered DMEM (pH 7.4) at 37 °e. After microinjection, cells
were replaced into NGF-containing serum-free DMEM and incubated
for the indicated times. To examine the effect of extracellular Ca2+,
microinjected cells were replaced into Hepes-buffered saline containing
140 mM NaCl, 4.7 mM KCl, 5 mM MgCh, 1.2 mM KH2P04, 11 mM
glucose, 2 mM EGTA, and 15 mM Hepes, pH 7.4. Cells were
photographed at x 400 magnification under the microscope with phase
contrast or by fluorescence of Texas red-coupled dextran. A neurite
was identified as a process greater than one cell body diameter in length.
For the quantitative examinations in Chapters 1 and 3, neurite-retracted
cells were defined as the cells that retracted by more than 10% of their
original length within 30 min of the addition of the agonist or of the
microinjection of recombinant proteins. For the quantitative
examinations in Chapter 2, neurite-retracted cells were defined as the
cells that almost completely retracted their neurites and caused rounding
of the cell body within 3 h of the microinjection of plasmids. To
.establish the time course in Chapter 3, the average neurite length was
measured from at least 30 cells in the same field, excluding the cells that
did not respond to the agonist. The percentages of neurite-retracted
cells were calculated by counting at least 30 microinjected cells in the
same field, and all data were obtained from triplicate experiments.
MLC Phosphorylation Assay
MLC phosphorylation assay was performed according to the
method of Amana et al. (28). The kinase reaction for ROKa was
carried out in 50 ~1 of the reaction mixture (50 mM Tris-HCl (pH 7.5),
2 mM EDTA, ImM dithiothreitol,' 7 mM MgCh, 0.1 % 3-[(3-
~56-
cholamidopropyl)dimethylammoniol-1-propanesulfonic acid, 250 uM
[y-32P]ATP (2.5 GBqlmmol), and 4 pg of purified MLC) with each
GST fusion protein (10 ng). After an incubation fOr 10 min at 30 OC,
the reaction mixtures were boiled in SDS-sample buffer and subjected to




    The auther appreciates gratefu11y to Professor Manabu Negishi,
Graduate School of Biostudies, Kyoto University, for his kind and
constant guidar}ce through the course of this work.
    The auther's appreciation is also given te Professor Atsushi
Ichikawa, Graduate School of Pharmaceutical Sciences, Kyoto
University, for his continuous support.
    And the auther as well thanks members of the Laboratory of
Molecular Neurobiology, Graduate School of Biostudies, Kyoto
University, for their helpful discussions and technical supports.
    Last, the auther heartily thanks my wife Yukiko and my parents for
their rnental encouragemeRt and persistent understanding and here




   Hironeri Katoh, Junko Aoki, Atsllshi Ichikawa, and
   Manabu Negishi (1998) p160 RhoA-Binding Kinase ROKct
   Induces Neurite Retraction. J. BioL Chem. 273, 2489-2492.
Chapter 2
   Hironori Katoh, Junko Aoki, Yoshiaki Yamaguchi,
   Yeshimi KitaRo, Atsushi Ichikawa, and Manabu Negishi
    (1998) Constitutively Active Gct12, Gct13, and Gorq Induce Rho-
    dependent Neurite Retraction through Different Signaling
    Pathways. J. Biol. Chem. 273, 28700-28707.
'
Chapter 3
    Hironori Katoh, Manabu Negishi, and Atsushi Ichikawa
    (1996) Prostaglandin E Receptor EP3 Subtype Induces Neurite
    Retraction via Small GTPase Rho. J. Biol. Chem. 271, 29780-
    29784.
    Junko Aoki, Hironori Katoh, Hidekazu Yasui, Yoshiaki
    Yamaguchi, Kazuhire Nakamura, Hiroshi Hasegawa,
    Atsushi Ichikawa and Manabu Negishi (1999) Signal
    Transduction Pathway Regulating Prostaglandin EP3 Receptor-
    induced Neurite Retraction. Biochem. J. 340, 365-369.
-59 --
REFERENCES
1. Goodman, C. S., and Shatz, C. J. (1993) Cell 10 (Supp!.), 77-98.
2. Keynes, R, and Cook, G. M. W. (1995) Cell 83, 161-169.
3. Hall, A. (1998) Science 279, 509-514.
4. Kaibuchi, K., Kuroda, S., and Amano, M. (1999) Annu. Rev. Biochem. 68,
459-486.
5. Kozma, R., Sarner, S., Ahmed, S., and Lim, L. (1997) Mol. Cell. BioI. 17,
1201-1211.
6. Gebbink, M. F. B. G., Kranenburg, 0., Poland, M., Horck, F. P. G., Houssa,
B., and Moolenaar, W. H. (1997) J. Cell BioI. 137, 1603-1613.
7. Daniels, R H., Hall P. S., and Bokoch, G. M. (1998) EMBO J. 17, 754-764.
8. Luo, L., Jan, L. Y., and Jan, Y.-N. (1997) Curro Opin. Neurobiol. 7, 81-86.
9. Threadgill, R, Bobb, K., and Ghosh, A (1997) Neuron 19, 625-634.
10. Ruchhoeft, M. L., Ohnuma, S., McNeill, L., Holt, C. E., and Harris, W. A
(1999) J. Neurosci. 19, 8454-8463.
11. Greene, L. A, and Tischler, A. S. (1976) Proc. Natl. Acad. Sci. U. S. A. 73,
2424-2428.
. 12. Tigyi, G., and Miledi, R (1992) J. BioI. Chem. 267, 21360-21367.
13. Dyer, D., Tigyi, G., and Miledi, R (1992) Mol. Brain Res. 14,293-301.
14. Sato, K., Tomura, R., Igarashi, Y., Ui, M., and Okajima, F. (1997) Biochem.
Biophys. Res. Commun. 240, 329-334.
15. Aktories, K., Weller, u., and Chhatwal, G. S. (1987) FEBS Lett. 212, 109-
113.
16. Sekine, A., Fujiwara, M., and Narumiya, S. (1989) J. BioI. Chem. 264, 8602-
8605.
17. Jalink, K.. Corven, E. J., Hengeveld, T .• Morii, N., Narumiya. S., and














                           'Tigyi, G., Fischer, D. J., Seb6k, A., Yang, C., Dyer, D. L., and Miledi, R.
(1996) J. IVeurochem. 66, 537-548.
Watanabe, G., Saito, Y., Madaule, P., Ishizaki, T., Fujisawa, K., Morii, N.,
Mukai, H., Ono, Y., Kakizuka, A., and Narumiya, S. (1996) Science 271, 645-
648.
Amano, M., Mukai, H., Ono, Y., Chihara, K., Matsui, T., Hamajima, Y.,
Okawa, K., Iwamatsu, A., and Kaibuchi, K. (1996) Science 271, 648-650.
Leung, T., Manser, E., Tan, L., and Lim, L. (1995) J. Biol. Chem. 270,
29051-29054.
Matsui, T., Amano, M., Yamamoto, T., Chihara, K., Nakafuku, M., Ito, M.,
Nakano, T,, Okawa, K., Iwamatsu, A., and Kaibuchi, K. (1996) EMBO J. 15,
2208-2216.
Nakagawa, O., Fujisawa, K,, Ishizaki, T., Saito, Y., Nakao, K., and Narumiya,
S. (1996) FEBS tett. 392, 189-193.
Reid, T., Furuyashiki, T., Ishizaki, T., Watanabe, G., Watanabe, N., Fujisawa,
K., Morii, N,, Madaule, P., and Narumiya, S. (1996) 1. Biol. Chem. 271,
13556-13560.
Watanabe, N., Madaule, P., Reid, T., Ishizaki, T., Watanabe, G., Kakizuka,
A., Saito, Y,, Nakao, K., Jockusch, B., M., and Narumiya, S. (1997) EMBO J.
16, 3044-3056.
Kimura, K., Ito, M., Amano, M., Chihara, K., Fukuta, Y., Nakafuku, M.,
Yamamori, B., Feng, J., Nakano, T,, Okavva, K., Iwamatsu, A., and Kaibuchi,
K. (1996) Science 273, 245-248.
Amano, M., Ito, M,, Kimura, K., Fukuta, Y., Chihara, K., Nakano, T.,
Matsuura, Y., and Kaibuchi, K. (1996) J. Biol. Chem. 271, 20246-20249
Leung, T., Chen, X.-Q., Manser, E., and Lim, L. (1996) Mol. Cell. Biel. 16,
5313-5327.
Amano, M., Chihara, K., Kimura, K., Fukuta, Y., Nakamura, N., Matsuura,
Y,, and Kaibuchi, K. (1997) Science 275, 1308-1311.
                        -61 --
30. Yasui, Y., Amano, M., Nagata, K., Inagaki, N., Nakamura, H., Saya, H.,
Kaibuchi, K., and Inagaki, M. (1998) 1. Cell Bio!. 143, 1249-1258.
31. Katoh, H., Negishi, M., and Ichikawa, A. (1996) J. BioI. Chem. 271, 29780-
29784.
32. Jalink, K., Eichholtz, T., Postma, F. R., Coven, E. J., and Moolenaar, W. H.
(1993) Cell Growth Differ. 4,247-255.
33. Kosako, H., Amano, M., Yanagida, M., Tanebe, K., Nishi, Y., Kaibuchi, K.,
and Inagaki, M. (1997) J. BioI. Chem.272, 10333-10336.
34. Hashimoto, R., Nakamura, Y., Kosako, H., Amana, M., Kaibuchi, K.,
Inagaki, M., and Takeda, M. (1999) Biochem. Biophys. Res. Commun. 263,
575-579.
35. Postma, F. R, Jalink, K., Hengeveld, T., and Moolenaar, W. H. (1996) EMBO
J. 15, 2388-2395.
36. Jalink, K, and Moolenaar, W. H. (1992) 1. Cell Bio!. 118,411-419.
37. Tigyi, G., Fischer, D. J., Sebok, A., Yang, c., Dyer, D. L., and Miledi, R.
(1996) J. Neurochem. 66, 549-558.
38. Strathmann M. P., and Simon, M. L (1991) Proc. Nat!' Acad. Sci. U. S. A. 88,
5582-5586.
"39. Xu, N., Bradley, L., Ambudukar, L, and Gutkind, J. S. (1993)" Proc. Natl.
Acad. Sci. U. S. A. 90, 6741-6745.
40. Voyno-Yasenetskya, T. A., Pace, A. M., and Bourne, H. R. (1994) Oncogene
9, 2559-2565.
41. Prasad, M. V. V. S. V., Dermott, J. M., Heasley, L. E., Johnson, G. L., and
Dhanasekaran, N. (1995) J. Bioi. Chem. 270, 18655-18659.
42. Collins, L. R., Minden, A., Karin, M., and Brown, 1. H. (1996) J. Bio!. Chem.
271, 17349-17353.
43. Voyno-Yasenetskya, T. A., Faure, M. P., Ahn, N. G., and Bourne, H. R.


















Buhl, A. M., Johnson, N. L., Dhanasekaran, N., and Johnson, G. L. (1995) J.
BioL Chem. 270, 24631-24634.
Gohla, A., Harhammer, R., and Schultz, G. (l998) J. Biol. Chem. 273, 4653-
4659.
Voyno-Yasenetskya, T. A,, Conklin, B. R., Gilbert, R. L, Hoolyey, R,
Bourne, H. R., and Barber, D. L. (1994) J. Biol. Chem. 269, 4721-4724.
Hooley, R., Chunn-Yuan, T., Symons, M., and Barber, D. L. (1996) 1. Biol.
Chem. 271, 6152-6158.
Lin, X., Voyno-Yasenetskya, T. A., Hooley, R., Lin. C.-Y., Orlowski, J., and
Barber, D. L. (1996) J. Biot. Chem. 271, 22604-22610.
Plonk, S. G., Park, S.-K., and Exton, J. H. (1998) J. Biol. Chem, 273, 4823-
4826.
Althoefer, H., Eversole-Cire, P., and Simon, M. I. (1997) J. BioL Chem. 272,
24380-24386.
Masters, S. B., Tyler Miller, R., Chi, M.-H., Chang, F.-H., Beiderman, B.,
Lopez, N, G., and Bourne, H. R, (1989) J. Biol. Chem. 264, 15467-15474.
Osawa, S., Danasekaran, N., Woon, C. W., and Johnson, G. L. (1990) Cetl
63, 697-706.
Nobes, C. D., Havvkins, P., Stephens, L., and Hall. A. (1995) J. Cell Sci. 108,
225-233,
Matthies, H. J. G., Palfrey, H, C., Himing, L. D., and Miller, R. J. (1987) J.
Neurosci. 7, 1198-1206.
Danasekaran, N., and Dermott, J. M. (1996) Cett. Signal. 8, 235-245.
Dhanasekaran, N., Vara Prasad, M. V. V. S., Wadsworth, S. J., Dermott, J.
M., and van Rossum, G.･<1994) J. BioL Chem. 269, 11802-11806.
Wadsworth, S. J., Gebauer, G., van Rossurn, G., and Danasekaran, N. (1997)
J. Biol. Chem. 272, 28829-28832,
Kuno, M., and Gardner, P. (1987) Nature 326, 301-304,
Irvine, R, F., and Moor, R. M. (1986) Biochem. J. 240, 917-920.



















Mochizuki-Oda, N., Nakajima, Y., Nakanishi, S., and Ito, S. (1994) J･ Biol･
Chem. 269, 9651-96S8.
Lev, S,, Moreno, H., Martinez, R., Canoll, P., Peles, E., Musacchio, J. M･,
Plowman, G. D., Rudy, B., and Schlessinger, J. (1995) Nature 376, 737-745･
Heasley, L. E., Storey, B., Fanger, G. R., Butterfiejd, L., Zamarripa, J.,
Blumberg, D., and Maue, R, A. (1996) MoL Cell. Biol. 16, 648-656.
Zheng, Y., Olson, M. F., Hal1, A., Cerione, R. A., and Toksoz, D. (!995) J.
Biol. Chem. 27e, 9031-9034.
Glaven, J. A., Whitehead, I. P., Nomanbhoy, T., Kay, R., and Cerione, R. A.
(1996) J. Biol. Chem. 271, 27374-27381.
Hait, M, J., Sharma, S., elMasry, N., Qiu, R.-G., McCabe, P., Polakis, P.,
and Bollag, G. (1996) J. Biol. Chem, 271, 25452--25458.
Jin, Z., and Strittmatter, S. M. (1997) J. Neurosci. 17, 6256-6263.
Threadgill, R., Bobb, K., and Ghosh, A. (1997) Neuron 19, 625-634,
Wolfe, L, S. (1982) J. Neurochem. 38, 1-14.
Milton,A. S., and Wendlandt, S. (1970) J. PhysieL, Lond. 207, 76-77.
Stitt, J. T. (1986) lhle X biol. Med. 59, 137-149.
Cljeda, S. R., and Campbel, W. B. (1982) Endocrinology. 111, 1031-1037,
Ferreira, S. H. (1972) Nature lVew Biol. 240, 200-203. ･
Roberts, P. J. and Hillier, K (1976) Brain Res. 112, 425-428. t
Reimann, W., Steinhauser, H. B., Hedler, L., Starke, K, and Hertting, G.
(1981) Eur. J. Pharmacol. 69, 421-427.
H61scher, C. (1995) Eun X Phann. 294, 253-259.
Negishi, M., Sugimoto, Y., and Ichikawa, A. (1995) Biochim Biophys. Acta.
1259, 109-120.
Coleman, R, A,, Kennedy, I., Humphrey, P. P. A., Bunce, K., and Lumley, P.
(1990) In Comprehensive Medicinal Chemistry (Hansch, C., Sammes, P. G.,
Taylor, J. B., and Emmett, J. C. eds.) 3, 643-714 Pergamon Press, Oxford.



















Coleman, R. A., Grix, S. P., Head, S. A., Louttit, J. B., Mallett, A,, and
Sheldrick, R. L. J. (1994) Prostaglandins 47, 151-168.
Krall J. F., Barrett J. D., Jamgotchian N. J. and KorenmaB S. G. (1984) J.
Endocrinol. Ie2, 329-336.
Chen M. C. Y., Amirian D. A., Toomey M., Sanders M. J. and Soll A. H.
(1988) Gastroenterology 94, 1121-l129.
Ohia S, E, and Jumblatt J. E. (1990) L Pharmacol. Exp. T7ierap. 2S5, 11-16.
Richelsen B. and Beck-Nielsen N. (1984) J. Lipid Res. 26, 127--134.
Garcia-Perez A. and Smith W. L. (1984) J. Ctin. invesL 74, 63-74,
Negishi, M., Ito, S. and Hayaishi, O. (l989) J. Biol. Chem. 264, 3916-3923.
Narnba T., Sugimoto Y., Negishi M., Irie A., Ushikubi F., Kakizuka A., Ito S.,
Ichikawa A. and Narumiya S. (1993) Natttre 365, 166-170.
Watabe, A., Sugimoto, Y., Honda, A., Irie, A., Namba, T., Negishi, M.,
Narumiya, S., and Ichikawa, A. (1993) J. Biol. Chem. 268, 20175-20178.
Katsuyama, M., Nishigaki, N., Sugimoto, Y., Morimoto, K., Negishi, M.,
Narumiya, S., and Ichikawa, A. (1995) FIEBS Lett. 372, l51-l56.
Sugimoto, Y., Namba, T., Honda, A., Hayashi, Y., Negishi, M., Ichikawa, A,
and Narumiya, S. (1992) J. BioL Chem. 267, 6463-6466.
Honda, A., Sugimoto, Y., Narnba, T., Watabe, A., Irie, A., Negishi, M.,
Narumiya, S., and Ichikawa, A. (1993) X BioL Chem. 268, 7759-7762.
Sugimoto, Y., Shigemoto, R., Namba, T., Negishi, M., Mizuno, N.,
Narumiya, S., and Ichikawa, A. (1994) Neurosci, 62, 919-928.
Nakamura, K, Kaneko, T., Yamashita, Y., Hasegawa, H., Katoh, K.,
Icl)ikawa, A., and Negishi, M. (1999) Neurosci. Lett. 26e, 1 17-120.
Exner, H. J., and Schlicker, E. (1995) Naunyn-Schmiedeberg's Arch.
Pharmacol. 351, 46-52.
Kumazawa, T., Mizumura, K., and Koda, H. (1993) Brain Res. 632, 321-324.
Lang, P., Gesbert, F,, Carmagnat, M, D., Stancou, R., Pouchelet, M., and
Bertoglio, J. (1996) EMBO J. 15, 51e-519.
                         -65-
95, Oida, H., Namba, T., Sugimoto, Y., Ushikubi, F., Ohishi, H., Ichikawa, A･,
    and Narumiya, S, (1995) Bn X Phamacot. 116, 2828-2837.
96. Ment, L R., Stewlart, W. B., Duncan, C. C., Pitt, B. R., and Cole, J. (1987) J･
    IVeurosurg. 67, 278-283.
97. Shohami, E., Shapira, Y., Sidi, A., and Cotev, S. (1987) L Cereb, Blood Flow
    Metab. 7, 58-63.
98. Dewitt, D. S., Kong, D. L, Lyeth, B. G., Jenkins, L. W., gayes, R. L.,
    Wooten, E. D., and Prough, D. S. (1988) L Neurotrauma. 5, 303-313.
99. Ellis, E. F., Police, R. J., Rice, L. Y., Grabeel, M., and Holt, S. (1989) L
    Neurotrauma. 6, 31-37.
100. Hertting, G., and Seregi, A. (1989) In T7ze Arachidonic Acid Cascade in the
    Nervous SYstem. Pait ll, 84-99.
101. Yamagata, K., Andreasson, K. I., Kaufniann, W, E., Barnes, C. A., and
    Worley, P. F. (1993) Neuron 11, 371-386.
102. Ito, W., Ishiguro, H., and Kurosawa, Y. (1991) Gene le2, 67-70.
103. Self, A. J., and Hall, A. (1995) Methods Enzymol. 256, 3-10.
104. FelgneT, P; L., Gadek, T. R., Holm, M., Roman, R., Chan, H. W., Wenz, M.,
    Northrep, J. P., Ringold, G. M, and Danielsen, M. (1987) Proc. Natl. Acad.
    Sci. UL S. A.84, 7413-7417.
'
-66-
